These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 37606849)

  • 1. Alopecia Areata: Current Treatments and New Directions.
    Dahabreh D; Jung S; Renert-Yuval Y; Bar J; Del Duca E; Guttman-Yassky E
    Am J Clin Dermatol; 2023 Nov; 24(6):895-912. PubMed ID: 37606849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
    Song CJ; Riley CA; Wilkison BD; Cho S
    Mil Med; 2024 Jun; ():. PubMed ID: 38850223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Janus kinase inhibitors for the treatment of alopecia areata].
    Kobal I; Ramot Y
    Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
    Trüeb RM; Dias MFRG
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
    Ramírez-Marín HA; Tosti A
    Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alopecia areata.
    Pratt CH; King LE; Messenger AG; Christiano AM; Sundberg JP
    Nat Rev Dis Primers; 2017 Mar; 3():17011. PubMed ID: 28300084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
    Donovan J
    Skin Therapy Lett; 2023 May; 28(3):1-7. PubMed ID: 37339501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
    Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
    J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alopecia areata: A multifactorial autoimmune condition.
    Simakou T; Butcher JP; Reid S; Henriquez FL
    J Autoimmun; 2019 Mar; 98():74-85. PubMed ID: 30558963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
    Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
    Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
    Hon KL; Luk DCK; Leung AKC; Ng C; Loo SKF
    Recent Pat Inflamm Allergy Drug Discov; 2020; 14(2):117-132. PubMed ID: 32723274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
    Paggioli I; Moss J
    J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
    Zheng C; Tosti A
    Dermatol Clin; 2021 Jul; 39(3):407-415. PubMed ID: 34053594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
    Bushwereb R; Srivastava G
    Ital J Dermatol Venerol; 2024 Aug; 159(4):380-389. PubMed ID: 38780910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.